These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22701315)

  • 1. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.
    Li YT; Chua MJ; Kunnath AP; Chowdhury EH
    Int J Nanomedicine; 2012; 7():2473-81. PubMed ID: 22701315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
    Tiash S; Chowdhury EH
    J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of siRNAs Against Selective Ion Channels and Transporter Genes Using Hyaluronic Acid-coupled Carbonate Apatite Nanoparticles Synergistically Inhibits Growth and Survival of Breast Cancer Cells.
    Uddin MB; Holl MMB; Chowdhury EH
    Int J Nanomedicine; 2024; 19():7709-7727. PubMed ID: 39099788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
    Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
    Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
    Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
    Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro.
    Zhi F; Dong H; Jia X; Guo W; Lu H; Yang Y; Ju H; Zhang X; Hu Y
    PLoS One; 2013; 8(3):e60034. PubMed ID: 23527297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
    Navarro G; Sawant RR; Biswas S; Essex S; Tros de Ilarduya C; Torchilin VP
    Nanomedicine (Lond); 2012 Jan; 7(1):65-78. PubMed ID: 22191778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
    Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
    Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
    Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
    Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
    Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Drug Resistant Breast Cancer.
    Huo Q; Yuan J; Zhu T; Li Z; Xie N
    Recent Pat Anticancer Drug Discov; 2021; 16(3):393-406. PubMed ID: 33602075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
    Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
    PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.